Anaphylaxis and Anaphylactic Shock

Allergic Reactions ◽

Children And Young People ◽

Blocking Agents ◽

Common Causes

Anaphylaxis is a serious allergic reaction that is rapid in onset and potentially fatal. Prompt recognition of the symptoms and institution of treatment are important in management. The lifetime prevalence of anaphylaxis is estimated to be 0.05% to 2% and appears to be increasing. Allergic reactions vary in severity, with the most severe culminating in anaphylactic shock. Common triggers include food, venom, and drugs. Triggers for events vary by age. Among children and young people, food is a common trigger; among middle-aged and older people, medications and venoms are common triggers. Neuromuscular blocking agents, antibiotics, and latex are the most common causes of anesthesia-associated anaphylaxis. This chapter briefly discusses the background, diagnosis, and management of anaphylaxis.

Previous safe administrations of neuromuscular blocking agents do not exonerate from the risk of anaphylactic shock

Annales Françaises d Anesthésie et de Réanimation ◽

10.1016/j.annfar.2008.05.005 ◽

2008 ◽

Vol 27 (6) ◽

pp. 509.e1-509.e3 ◽

Cited By ~ 1

Author(s):

V. Cottenceau ◽

P. Dewachter ◽

K. Nouette-Gaulain ◽

F. Sztark

Keyword(s):

Anaphylactic Shock ◽

Neuromuscular Blocking ◽

New Neuromuscular Blocking Agents

10.1007/978-3-642-70682-0 ◽

1986 ◽

Cited By ~ 5

Keyword(s):

Neuromuscular Blocking ◽

Faculty Opinions recommendation of Is time to peak effect of neuromuscular blocking agents dependent on dose? Testing the concept of buffered diffusion.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.1120236.576398 ◽

2008 ◽

Author(s):

Harald Ihmsen

Keyword(s):

Peak Effect ◽

Neuromuscular Blocking ◽

Time To Peak ◽

Faculty Opinions recommendation of Intermediate acting non-depolarizing neuromuscular blocking agents and risk of postoperative respiratory complications: prospective propensity score matched cohort study.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.717961665.793463852 ◽

2012 ◽

Author(s):

Nicolas Bruder ◽

Axel Maurice-Szamburski

Keyword(s):

Cohort Study ◽

Propensity Score ◽

Neuromuscular Blocking ◽

Postoperative Respiratory Complications

Matched Cohort ◽

Respiratory Complications ◽

Matched Cohort Study ◽

Blocking Agents ◽

Faculty Opinions recommendation of Six years without pholcodine; Norwegians are significantly less IgE-sensitized and clinically more tolerant to neuromuscular blocking agents.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.726994902.793531467 ◽

2017 ◽

Author(s):

Sherwood Burge

Keyword(s):

Neuromuscular Blocking ◽

Dosing of neuromuscular blocking agents in patients with obesity: A narrative review

Anaesthesia and Intensive Care ◽

10.1177/0310057x20968573 ◽

2021 ◽

pp. 0310057X2096857

Author(s):

Brian L Erstad ◽

Jeffrey F Barletta

Keyword(s):

Body Weight ◽

Ideal Body Weight ◽

Neuromuscular Blocking ◽

Patient Specific ◽

Lean Body Weight ◽

Short Term ◽

Blocking Agents ◽

Ideal Body ◽

Size Descriptor

There is no consensus on which weight clinicians should use for weight-based dosing of neuromuscular blocking agents (NMBAs), as exemplified by differing or absent recommendations in clinical practice guidelines. The purpose of this paper is to review studies that evaluated various size descriptors for weight-based dosing of succinylcholine and non-depolarising NMBAs, and to provide recommendations for the descriptors of choice for the weight-based dosing of these agents in patients with obesity. All of the studies conducted to date involving depolarising and non-depolarising NMBAs in patients with obesity have assessed single doses or short-term infusions conducted in perioperative settings. Recognising that any final dosing regimen must take into account patient-specific considerations, the available evidence suggests that actual body weight is the size descriptor of choice for weight-based dosing of succinylcholine and that ideal body weight, or an adjusted (or lean) body weight, is the size descriptor of choice for weight-based dosing of non-depolarising NMBAs.